Advertisement

Topics

Companies Related to "Liver Cancer Pipeline Review 2015" [Most Relevant Company Matches] - Page: 2 RSS

13:14 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Liver Cancer Pipeline Review 2015" found in our extensive corporate database of over 50,000 company records.

Showing "Liver Cancer Pipeline Review 2015" Companies 26–50 of 3,500+

Relevant

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...


Vesta Therapeutics, Inc

Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. Clinicians in academic settings have found that, following administration, huma...

Vicus Therapeutics, LLC

Vicus Therapeutics is a biopharmaceutical company dedicated to bringing breakthrough therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar ...


Delcath Systems

Our objective is to establish the use of the Delcath system as the standard technique for delivering chemotherapy agents to the liver and to expand the Delcath technology so that it may be used in the treatment of other liver diseases and of cancers in other parts of the body. Our strategy includes the following: Complete clinical trials to obtain FDA approval for the Delcath system with doxorubi...

ReproCELL, Inc.

“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year. Read on for details.

Onconome, Inc.

Onconome is dedicated to the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon, bladder and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. Our serum tests for early detection of prostate and colon cancer and our urine test for bladder cancer...

Cleveland Diagnostics, Inc.

Cleveland Diagnostics, Inc., is a clinical-stage biotechnology company developing technology to improve cancer diagnostics. Its Solvent Interaction Analysis (SIA) technology investigates biomarkers at the structural level as opposed to overall concentration, giving better insights as to its cellular origin. Its pipeline of high performance, non-invasive ca...

MDReview

MDReview provides highly effective and innovative physician peer review, delivered with the utmost integrity. MDReview’s main purpose is to support hospitals in making some of the most important decisions that are at the heart of their quality management efforts. With a national reach to a diverse client base in all 50 state, MDReview is the standard ...

Galil Medical

Ultra-high resolution cryo-surgical device. FDA-approved and effective for prostate cancer, liver cancer and many other applications. System uses needle-probes (1.5mm) to directly freeze localized tissue. 2mm and 3mm probes are available for use in conjunction with IMRI. Galil offers full technical and clinical support for our new-generation cryo system.

Arbios Systems, Inc.

Arbios Systems, Inc. is developing proprietary medical devices and cell-based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET™ Liver Assist Device, a novel blood purification therapy that provides enhanced “liver dialysis,” and the H...

Sirtex Medical

The primary objective of SIRTeX Medical is to research, develop, and commercialise effective treatments for liver cancer using novel small particle technology.

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...

Jennerex Biotherapeutics, Inc.

Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company’s lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, ...

Advarra

Advarra, headquartered in Columbia, MD, provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. Its robust regulatory expertise and innovative technology ensure the highest standards of research ...

Exalenz Bioscience, Inc.

Exalenz Bioscience develops and markets medical equipment for breath testing for the purposes of diagnosis and management of digestive system and liver conditions. The company sells the BreathID® System together with proprietary disposable test kits. The BreathID® System has been proven effective for clinical use in the task of identifying the presen...

Cell Works Incorporated

Cell Works Inc. is an early-stage biomedical company located in Baltimore, Maryland, basing their initial products on research conducted at The Johns Hopkins University (JHU). Cell Works has exclusively licensed certain cell isolation technology from JHU on a worldwide basis. This technology license currently incorporates one patent, one patent application, and related international patent applica...

AlphaNet

Alpha-1 Antitrypsin Deficiency is a leading genetic killer of adults and a leading cause of liver transplants in children. It is estimated that 20 million Americans are undetected carriers of the Alpha-1 gene and may be at risk for lung and/or liver disease. Only 10 percent of the estimated 100,000 with severe deficiency of Alpha-1 have been diagnosed.

BIND Therapeutics and Navidea Biopharmaceuticals

BIND Therapeutics is a clinical-stage nanomedicine platform company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeli...

Kanzius Cancer Research Foundation

The Kanzius Cancer Research Foundation is a 501(c)(3) non-profit organization with a mission to create national and global awareness of the potentials of the Kanzius Noninvasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses to human trials. The goal of KCRF is to raise money to support ongoing research grants. Pancreatic, liver and colorectal cance...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

FeRx Incorporated

The Company is focused on the development and commercialization of its proprietary Magnetic Targeted Carrier ("MTC") technology for the site specific delivery and sustained release of pharmaceutical agents. FeRx's lead compound, MTC-Doxorubicin, is in Phase I/II clinical trials in patients with liver cancer.

Chesapeake IRB

Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality...

Oxford BioTherapeutics (OBT)

Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody medicines for oncology. OBT's strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP(R) proteomic database. OBT is in an unrivalled position to convert its novel targets into a successful therapeutic pipeline throug...

iQur Ltd

iQur® is a specialty pharmaceutical company at the forefront of international breakthroughs in the detection, treatment and monitoring of Hepatitis C and other liver diseases.iQur exists to provide clinicians with a comprehensive, 24–48 hour service for genotyping, qualitation and quantification of both the Hepatitis C (HCV) and Hepatitis B (HBV) viruses.Founded in 2003 by liver disease special...


More From BioPortfolio on "Liver Cancer Pipeline Review 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks